Department of Hematology and Oncology with Palliative Care, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
Department of Internal Medicine, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
Oncol Res Treat. 2022;45(3):112-117. doi: 10.1159/000520572. Epub 2021 Nov 1.
Coronavirus disease 2019 (COVID-19) cases in Germany, as in most other places in Europe or worldwide, are still highly prevalent. Vaccination rates currently remain low, putting cancer patients at a continued risk of infection with SARS-CoV-2, while prevalence of SARS-CoV-2 antibodies among cancer patients in Germany remains essentially unknown.
Between August 2020 and February 2021, patients admitted to our hospital were prospectively enrolled in our COVID-19 biobank. Collected sera were analyzed for SARS-CoV-2-IgM/IgG using Elecsys Anti-SARS-CoV-2 assay.
One hundred and ten patients with cancer were included in this study. With 71 (65%) patients, most had active cancer treatment, mainly chemotherapy (56%). The most frequent diagnosis was gastrointestinal cancer (54%) with pancreatic cancer being the most common cancer type (24%). Hematologic malignancies were present in 21 patients (17%). Among the cancer patients first diagnosed during the pandemic, the rate of palliative treatment situations tended to be higher (76% vs. 67%, p = 0.17). A history of SARS-CoV-2 infection was documented in 15 (14%) patients; however, SARS-CoV-2 antibodies were detected in 10 (67%) patients only. Of the patients without a history of SARS-CoV-2 infection, none displayed SARS-CoV-2 antibodies.
In the present single-center experience, a low serological prevalence of SARS-CoV-2 antibodies among cancer patients even after SARS-CoV-2 infection was found. The results support continued strict preventive measures as well as efforts toward faster vaccination, due to a low immunity level in the population.
与欧洲或世界其他大多数地区一样，德国的 2019 年冠状病毒病（COVID-19）病例仍然非常普遍。疫苗接种率目前仍然很低，使癌症患者继续面临感染 SARS-CoV-2 的风险，而德国癌症患者中 SARS-CoV-2 抗体的流行率仍基本未知。
在 2020 年 8 月至 2021 年 2 月期间，我院收治的患者被前瞻性纳入我们的 COVID-19 生物库。使用 Elecsys Anti-SARS-CoV-2 检测法分析收集的血清中 SARS-CoV-2-IgM/IgG。
本研究共纳入 110 例癌症患者。71 例（65%）患者正在接受癌症治疗，主要为化疗（56%）。最常见的诊断是胃肠道癌（54%），其中胰腺癌是最常见的癌症类型（24%）。21 例患者患有血液系统恶性肿瘤（17%）。在大流行期间首次诊断的癌症患者中，姑息治疗情况的比例较高（76%比 67%，p=0.17）。有 15 例（14%）患者有 SARS-CoV-2 感染史；然而，仅在 10 例（67%）患者中检测到 SARS-CoV-2 抗体。在没有 SARS-CoV-2 感染史的患者中，没有患者出现 SARS-CoV-2 抗体。
在本单中心经验中，即使在 SARS-CoV-2 感染后，癌症患者中 SARS-CoV-2 抗体的血清流行率也较低。由于人群免疫力水平较低，这些结果支持继续采取严格的预防措施，并努力加快疫苗接种。
